RecruitingPhase 2NCT06662006

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Principal Investigator
Juan Du
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intervention
nal-IRI,5-fu,LV, benmelstobart, anlotinib(drug)
Enrollment
56 enrolled
Eligibility
18-75 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06662006 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials